AFU Substrate for Primary Liver Cancer Detection

Primary liver cancer (PHC) stands as one of the prevalent malignant tumors in China, characterized by its high malignancy, rapid progression, poor prognosis, and formidable invasiveness. It holds the third-highest mortality rate among digestive system malignancies, trailing only gastric and esophageal cancers. Early diagnosis and early intervention are pivotal in extending survival and lowering mortality rates.

 

 

 

 

Background of AFU Substrate Research and Development

While Alpha-fetoprotein (AFP) serves as a crucial indicator in PHC diagnosis, 30% to 40% of PHC patients present as AFP-negative. Consequently, the exploration of more specific and sensitive tumor markers and diagnostic methods becomes imperative in liver cancer research. Serum AFU levels in liver cancer patients exhibit marked distinctions from those with other hepatobiliary diseases, showing a significant elevation. Animal experiments have demonstrated that AFU activity in Morris mouse liver cancer tissue is seven times higher than that in normal liver tissue, indicating its potential as a nonspecific marker for liver cancer. The diagnostic accuracy for this disease ranges from 73.9% to 81%, with a specificity of 90%. Notably, there is no substantial difference in AFU positivity rates between liver cancer patients who test positive or negative for AFP.

 

 

AFU detection Detection principle

 

CNP-AFU

Substrate:CNP-AFU (2-chloro-4-nitrobenzene-α-L-Fucoside) a>

English name:2-Chloro-4-nitrophenyl-α-L-fucopyranoside

Alias:CNP-AFU

Molecular formula:C12H14NO7Cl

Molecular weight:319.80

CAS:157843-41-9

 

Principle: AFU in serum acts on the substrate to generate 2-chloro-4-nitrobenzene (CNP). The change rate of CNP absorbance per minute is measured at a wavelength of 405nm. (ΔA/min), calculate its activity.

 

Advantage:

1. Specific reaction with AFU;

2. The measurement is simple, fast and sensitive;

3. Suitable for automatic biochemical analyzers.

 

 

M-G-CNP-AFU

Substrate:M-G-CNP-AFU (modified complex substrate M-G-2-chloro-4-nitrobenzene-α-L-Fucoseglycoside)

English name:M-G-CNP-AFu

Molecular formula:[CH2CH(OSO3K)]n C12H14NO7Cl

Molecular weight:3542.6

 

Measurement principle: AFU in serum acts on the substrate to generate M+ G+2-chloro-4-nitrobenzene (CNP). CNP is measured at a wavelength of 405nm every minute. The change rate of CNP absorbance (ΔA/min) was used to calculate its activity.

 

Advantages: Further improves the stability, solubility and interference resistance of the substrate.

 

 

AFU Detection Clinical Significance

 

Reduces fucosidosis (hereditary fucosidase deficiency)

 

Elevated diagnosis of primary liver cancer

 

Monitoring the therapeutic effect of chronic hepatitis and cirrhosis

 

 

AFU Substrate for Detection Product List

Item number	Product name	level
DCE0001A	Chloronitrobenzene-α-L-fucoside (CNP-AFU)	≥99%
ECE0056A	M-G-2-chloro-4-nitrobenzene-α-L-fucoside (M-G-CNP-AFu)	98.50%

 

For more product details, please contact us: service@seebio.cn or Phone: +86 21 58183719 or Wechat: +86 158 0195 7578